drug
birch triterpenes
Marketedupdated 3mo agoby Chiesi USA Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying birch triterpenes
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 18, 2028
~2.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jan 4, 2039formulationUS 11083733
- Jan 4, 2039method-of-use (U-3811)US 11266660
- Jan 4, 2039method-of-use (U-3811)US 12268695
- Nov 24, 2030method-of-use (U-3811)US 93520414.3y
- Nov 24, 2030method-of-use (U-3811)US 98272144.3y
- Jun 21, 2026formulationUS 8828444
FDA exclusivities (2)
- Dec 18, 2030ODE-460Orphan Drug (7y)4.3y
- Dec 18, 2028NCENew Chemical Entity (5y)2.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that